Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Trial Profile

Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Elagolix (Primary)
  • Indications Endometriosis
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms Elaris EM-III; EM-III
  • Sponsors AbbVie
  • Most Recent Events

    • 01 Nov 2017 Results (n=569) assessing self reported improvements in endometriosis associated pelvic pain (dysmenorrhea and non menstrual pelvic pain), dyspareunia, and quality of life using patient data from Elaris EM-III and Elaris EM-IV trials presented at the American Society for Reproductive Medicine Scientific Congress 2017
    • 01 Nov 2017 Results assessing long term safety and efficacy of elagolix using patients data from Elaris EM-III and Elaris EM-IV trials presented at the American Society for Reproductive Medicine Scientific Congress 2017
    • 01 Nov 2017 Results (n=569) assessing long term effects of Elagolix on the bone mineral density using patient data from Elaris EM-III and Elaris EM-IV trials presented at the American Society for Reproductive Medicine Scientific Congress 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top